Last reviewed · How we verify

Intravenous anesthetic — Competitive Intelligence Brief

Intravenous anesthetic (Intravenous anesthetic) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA-A receptor agonist / NMDA receptor antagonist (class-dependent). Area: Anesthesiology.

marketed GABA-A receptor agonist / NMDA receptor antagonist (class-dependent) GABA-A receptor or NMDA receptor (varies by specific agent) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous anesthetic (Intravenous anesthetic) — University of Pennsylvania. Intravenous anesthetics work by enhancing inhibitory GABAergic neurotransmission and/or blocking excitatory glutamatergic signaling in the central nervous system to produce rapid unconsciousness.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous anesthetic TARGET Intravenous anesthetic University of Pennsylvania marketed GABA-A receptor agonist / NMDA receptor antagonist (class-dependent) GABA-A receptor or NMDA receptor (varies by specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA-A receptor agonist / NMDA receptor antagonist (class-dependent) class)

  1. University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous anesthetic — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-anesthetic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: